Baxter International Spends Close To $1B On Cancer Drugmaker American health care company Baxter International has purchased two cancer drugs from Sigma-Tau Finanziaria SpA valued at $900 million. Both drugs are designed to treat patients with a rare form of blood cancer called acute lymphoblastic leukemia. by Ted Ranosa